| Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists W Toy, H Weir, P Razavi, M Lawson, AU Goeppert, AM Mazzola, A Smith, ... Cancer discovery 7 (3), 277-287, 2017 | 345 | 2017 |
| The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models ST Durant, L Zheng, Y Wang, K Chen, L Zhang, T Zhang, Z Yang, ... Science advances 4 (6), eaat1719, 2018 | 244 | 2018 |
| AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity JHL Fok, A Ramos-Montoya, M Vazquez-Chantada, PWG Wijnhoven, ... Nature communications 10 (1), 5065, 2019 | 240 | 2019 |
| Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo S Ashton, YH Song, J Nolan, E Cadogan, J Murray, R Odedra, J Foster, ... Science translational medicine 8 (325), 325ra17-325ra17, 2016 | 218 | 2016 |
| Preclinical comparison of the blood–brain barrier permeability of osimertinib with other EGFR TKIs N Colclough, K Chen, P Johnström, N Strittmatter, Y Yan, GL Wrigley, ... Clinical Cancer Research 27 (1), 189-201, 2021 | 134 | 2021 |
| Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically LC Riches, AG Trinidad, G Hughes, GN Jones, AM Hughes, ... Molecular cancer therapeutics 19 (1), 13-25, 2020 | 122 | 2020 |
| The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient–derived xenograft models AG Schuller, ER Barry, RDO Jones, RE Henry, MM Frigault, G Beran, ... Clinical Cancer Research 21 (12), 2811-2819, 2015 | 74 | 2015 |
| Orally bioavailable and blood–brain barrier-penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice J Karlin, J Allen, SF Ahmad, G Hughes, V Sheridan, R Odedra, ... Molecular cancer therapeutics 17 (8), 1637-1647, 2018 | 58 | 2018 |
| Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT … JG Kettle, R Anjum, E Barry, D Bhavsar, C Brown, S Boyd, A Campbell, ... Journal of Medicinal Chemistry 61 (19), 8797-8810, 2018 | 53 | 2018 |
| Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper G Illuzzi, AD Staniszewska, SJ Gill, A Pike, L McWilliams, SE Critchlow, ... Clinical Cancer Research 28 (21), 4724-4736, 2022 | 50 | 2022 |
| A rapid computational filter for predicting the rate of human renal clearance SW Paine, P Barton, J Bird, R Denton, K Menochet, A Smith, ... Journal of Molecular Graphics and Modelling 29 (4), 529-537, 2010 | 45 | 2010 |
| Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers RM England, JI Hare, J Barnes, J Wilson, A Smith, N Strittmatter, ... Journal of Controlled Release 247, 73-85, 2017 | 42 | 2017 |
| ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156 B Koneru, A Farooqi, TH Nguyen, WH Chen, A Hindle, C Eslinger, ... Science translational medicine 13 (607), eabd5750, 2021 | 40 | 2021 |
| Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response T Petreus, E Cadogan, G Hughes, A Smith, V Pilla Reddy, A Lau, ... Communications Biology 4 (1), 1001, 2021 | 34 | 2021 |
| Selumetinib-based therapy in uveal melanoma patient-derived xenografts D Decaudin, R El Botty, B Diallo, G Massonnet, J Fleury, A Naguez, ... Oncotarget 9 (31), 21674, 2018 | 29 | 2018 |
| The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy J Greene, A Nguyen, SM Bagby, GN Jones, WM Tai, KS Quackenbush, ... Oncotarget 8 (67), 110904, 2017 | 22 | 2017 |
| Evaluation of laser diode thermal desorption (LDTD) coupled with tandem mass spectrometry (MS/MS) for support of in vitro drug discovery assays: Increasing scope, robustness … I Beattie, A Smith, DJ Weston, P White, S Szwandt, L Sealey Journal of pharmaceutical and biomedical analysis 59, 18-28, 2012 | 22 | 2012 |
| Method to visualize the intratumor distribution and impact of gemcitabine in pancreatic ductal adenocarcinoma by multimodal imaging N Strittmatter, FM Richards, AM Race, S Ling, D Sutton, A Nilsson, ... Analytical Chemistry 94 (3), 1795-1803, 2022 | 21 | 2022 |
| AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor … V Flemington, EJ Davies, D Robinson, LC Sandin, O Delpuech, P Zhang, ... Molecular cancer therapeutics 20 (2), 238-249, 2021 | 16 | 2021 |
| Quantifying drug‐induced bone marrow toxicity using a novel haematopoiesis systems pharmacology model C Fornari, L Oplustil O'Connor, C Pin, A Smith, JWT Yates, SYA Cheung, ... CPT: Pharmacometrics & Systems Pharmacology 8 (11), 858-868, 2019 | 15 | 2019 |
